Lupin secures Plasil licensing deal for Philippines, Brazil gastroenterology market

Global pharmaceutical major Lupin Limited announced that its subsidiaries, Multicare Pharmaceuticals (Philippines) and MedQuimica (Brazil), have entered into an exclusive licensing agreement with Italian pharmaceutical company Neopharmed Gentili. The agreement grants Lupin marketing and promotional rights for the gastroenterology brand Plasil (metoclopramide) in the Philippines and Brazil.

This partnership aims to bolster Lupin’s gastroenterology offerings and expand its presence in these emerging markets. Neopharmed will supply the product in the Philippines, while production for Brazil will transition to Medquimica’s manufacturing facility. The agreement leverages Lupin's established local presence, regulatory expertise, and commercial capabilities.

Plasil is noted for its effectiveness in treating nausea, vomiting, and motility disorders. According to Fabrice Egros, president of corporate development at Lupin, this collaboration will broaden patient access and deliver meaningful health outcomes. Matteo Meazzini, director of business development at Neopharmed Gentili, highlighted the agreement's role in expanding Neopharmed's international footprint.